PT3066097T - Sais do ácido 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidino-5-carboxílico - Google Patents

Sais do ácido 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidino-5-carboxílico Download PDF

Info

Publication number
PT3066097T
PT3066097T PT147935654T PT14793565T PT3066097T PT 3066097 T PT3066097 T PT 3066097T PT 147935654 T PT147935654 T PT 147935654T PT 14793565 T PT14793565 T PT 14793565T PT 3066097 T PT3066097 T PT 3066097T
Authority
PT
Portugal
Prior art keywords
dihydro
compound
oxo
methyl
dioxo
Prior art date
Application number
PT147935654T
Other languages
English (en)
Portuguese (pt)
Inventor
Ackerstaff Jens
Olenik Britta
Keil Birgit
Hinz Martin-Holger
Fürstner Chantal
Jeske Mario
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PT3066097T publication Critical patent/PT3066097T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT147935654T 2013-11-08 2014-11-05 Sais do ácido 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidino-5-carboxílico PT3066097T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192177 2013-11-08

Publications (1)

Publication Number Publication Date
PT3066097T true PT3066097T (pt) 2017-11-10

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147935654T PT3066097T (pt) 2013-11-08 2014-11-05 Sais do ácido 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidino-5-carboxílico

Country Status (32)

Country Link
US (1) US9926305B2 (enExample)
EP (1) EP3066097B1 (enExample)
JP (1) JP6446051B2 (enExample)
KR (1) KR102351418B1 (enExample)
CN (1) CN105658647B (enExample)
AP (1) AP2016009181A0 (enExample)
AU (1) AU2014345599B2 (enExample)
BR (1) BR112016010253A8 (enExample)
CA (1) CA2929780C (enExample)
CL (1) CL2016001096A1 (enExample)
CY (1) CY1119520T1 (enExample)
DK (1) DK3066097T3 (enExample)
EA (1) EA033132B1 (enExample)
ES (1) ES2645480T3 (enExample)
HR (1) HRP20171603T1 (enExample)
HU (1) HUE035021T2 (enExample)
IL (1) IL245407B (enExample)
LT (1) LT3066097T (enExample)
MA (1) MA39020A1 (enExample)
ME (1) ME02907B (enExample)
MX (1) MX366848B (enExample)
MY (1) MY190108A (enExample)
NO (1) NO3066097T3 (enExample)
PH (1) PH12016500853B1 (enExample)
PL (1) PL3066097T3 (enExample)
PT (1) PT3066097T (enExample)
RS (1) RS56509B1 (enExample)
SA (1) SA516371082B1 (enExample)
SI (1) SI3066097T1 (enExample)
TN (1) TN2016000170A1 (enExample)
UA (1) UA117686C2 (enExample)
WO (1) WO2015067652A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) * 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
CA3255475A1 (en) * 2022-04-05 2023-10-12 Socpra Sciences Santé Et Humaines S.E.C. CHYMASE INHIBITORS INTENDED FOR USE IN THE SELECTIVE RESOLUTION OF THROMBUS IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295952A1 (en) * 2000-10-19 2002-04-29 Nippon Kayaku Kabushiki Kaisha Novel remedies or preventives for angiostenosis
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
CN107660798A (zh) * 2012-03-05 2018-02-06 格拉图克技术私人有限公司 膳食补充剂
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
JP2016535769A (ja) * 2013-11-08 2016-11-17 バイエル ファーマ アクチエンゲゼルシャフト キマーゼ阻害薬としての置換されているウラシル類

Also Published As

Publication number Publication date
IL245407A0 (en) 2016-06-30
BR112016010253A2 (pt) 2017-08-08
DK3066097T3 (da) 2017-11-06
AU2014345599A1 (en) 2016-05-19
MY190108A (en) 2022-03-29
MX2016005971A (es) 2016-08-11
CL2016001096A1 (es) 2016-12-23
HUE035021T2 (en) 2018-03-28
EP3066097A1 (de) 2016-09-14
NO3066097T3 (enExample) 2018-01-13
MA39020A1 (fr) 2017-04-28
HRP20171603T1 (hr) 2017-12-01
PL3066097T3 (pl) 2018-01-31
SA516371082B1 (ar) 2019-05-16
HK1222171A1 (zh) 2017-06-23
PH12016500853B1 (en) 2021-03-24
EA033132B1 (ru) 2019-08-30
ME02907B (me) 2018-04-20
KR20160078980A (ko) 2016-07-05
KR102351418B1 (ko) 2022-01-17
ES2645480T3 (es) 2017-12-05
IL245407B (en) 2019-10-31
RS56509B1 (sr) 2018-02-28
LT3066097T (lt) 2018-02-12
PH12016500853A1 (en) 2016-06-20
NZ719532A (en) 2021-06-25
JP6446051B2 (ja) 2018-12-26
CN105658647A (zh) 2016-06-08
WO2015067652A1 (de) 2015-05-14
BR112016010253A8 (pt) 2021-06-22
TN2016000170A1 (en) 2017-10-06
MX366848B (es) 2019-07-26
AP2016009181A0 (en) 2016-04-30
UA117686C2 (uk) 2018-09-10
EA201600381A1 (ru) 2016-10-31
CY1119520T1 (el) 2018-03-07
US20160289220A1 (en) 2016-10-06
AU2014345599B2 (en) 2019-02-14
JP2016535096A (ja) 2016-11-10
SI3066097T1 (sl) 2017-12-29
CN105658647B (zh) 2019-09-06
EP3066097B1 (de) 2017-08-16
CA2929780A1 (en) 2015-05-14
CA2929780C (en) 2022-03-22
US9926305B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
ES2329670T3 (es) Derivados de piridazina.
CN102256984B (zh) 制备二胺衍生物的方法
AU2003240259A1 (en) Aryloximes
BR112014028086A2 (pt) uracilas biciclicamente substituídas e o uso das mesmas
WO2019191654A1 (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
JP2019524710A5 (enExample)
PT3066097T (pt) Sais do ácido 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidino-5-carboxílico
EP3759095A1 (en) Compounds and compositions for treating conditions associated with apj receptor activity
WO2016145622A1 (zh) 苯并咪唑衍生物及其制备方法和医药用途
TW201245183A (en) Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
ES2349622T3 (es) Benzoilpiridazinas.
HK1222171B (zh) 化合物的盐
NZ719532B2 (en) Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid
CN111793066B (zh) 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用
CN111655686B (zh) 四氢异喹啉类衍生物及其制备方法和用途
CN109232538B (zh) 一种1,2,4-三氮唑类化合物
HK1223925B (zh) 醛糖还原酶抑制剂及其用途
HK1162024A (en) Acid addition salt of udenafil, preparation method thereof and pharmaceutical composition comprising the same
JP2012512206A (ja) 4−({(4−カルボキシブチル)[2−(2−{[4−(2−フェニルエチル)ベンジル]オキシ}フェニル)エチル]−アミノ}メチル)安息香酸の一水和物
CN107434791A (zh) 新型醛糖还原酶抑制类化合物及其制备方法和在医学上的应用
JPWO2001013916A1 (ja) 細胞死を抑制する薬剤